Download a complete bibliography from each of our ongoing investigational programs below.
Tebipenem HBR
Oral tebipenem as step-down therapy following intravenous ertapenem in a 7-day hollow-fiber in vitro infection model
Tebipenem HBR
In vitro analysis of AmpC β-lactamase induction by tebipenem in Enterobacterales and Pseudomonas aeruginosa
Tebipenem HBR
In vitro activity of tebipenem against relevant clinical isolates in the presence of pulmonary surfactant
Tebipenem HBR
In vitro activity of tebipenem and comparators against Enterobacterales collected from patients with bloodstream infections as part of the 2019 global STEWARD surveillance program
Tebipenem HBR
High prevalence of fluoroquinolone-resistant urinary tract infection among US emergency department patients diagnosed with UTI, 2018-2020
Tebipenem HBR
Molecular epidemiology of Escherichia coli causing urinary tract infections in United States and in vitro activity of tebipenem, including against strain lineage and resistant subsets (2018–2020)
Tebipenem HBR
Epidemiology and 12-month antibiotic use in the outpatient setting among adult patients with complicated urinary tract infections: a retrospective database analysis
Tebipenem HBR
A validated sensitive and selective ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for quantitative analysis of tebipenem pivoxil and tebipenem, in human whole blood and its application in a pharmacokinetic study in healthy human volunteers
SPR206
Bruss J, Lister T, Gupta VK, et al. Single- and Multiple-Ascending-Dose Study of the Safety, Tolerability, and Pharmacokinetics of the Polymyxin Derivative SPR206. Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0073921.
SPR720
Talley AK, Thurston A, Moore G, et al. First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of SPR720, a Novel Oral Bacterial DNA Gyrase (GyrB) Inhibitor for Mycobacterial Infections. Antimicrob Agents Chemother. 2021 Sep 7:AAC0120821.
SPR720
Pidot SJ, Porter JL, Lister T, Stinear TP. In vitro activity of SPR719 against Mycobacterium ulcerans, Mycobacterium marinum and Mycobacterium chimaera. PLoS Negl Trop Dis. 2021 Jul 26;15(7):e0009636.
Tebipenem HBR
Pharmacokinetics of oral tebipenem pivoxil hydrobromide in subjects with varying degrees of renal impairment
Tebipenem HBR
Agar dilution versus broth microdilution of tebipenem against ESBL-producing Enterobacterales
Tebipenem HBR
In vitro minimum inhibitory and minimum bactericidal concentrations of tebipenem and comparators against contemporary Enterobacterales tested in pooled human urine at varied pH
Tebipenem HBR
Activity of tebipenem against a set of recent clinical isolates from urinary tract and upper respiratory tract infections
SPR720
Characterization of resistance to DNA gyrase inhibitor SPR719 in Mycobacterium avium
Tebipenem HBR
Gupta VK, Maier G, Eckburg P, et al. A randomized, double-blind, placebo- and positive-controlled crossover study of the effects of tebipenem pivoxil hydrobromide on QT/QTc intervals in healthy subjects. Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0014521.
Tebipenem HBR
Lodise TP, Chopra T, Nathanson BH, Sulham K. Hospital admission patterns of adult patients with complicated urinary tract infections who present to the hospital by disease acuity and comorbid conditions: How many admissions are potentially avoidable? Am J Infect Control. 2021 May 30:S0196-6553(21)00382-5.
Tebipenem HBR
Oral tebipenem pivoxil hydrobromide is non-inferior to IV ertapenem in complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) – Results from the pivotal ADAPT-PO study.
Tebipenem HBR
Health resource utilization in patients with complicated urinary tract infections (cUTI) and antibiotic resistance or treatment failure: a retrospective database analysis
Tebipenem HBR
Tebipenem: An oral carbapenem with activity against multi-drug resistant urinary tract infection isolates of Escherichia coli collected from US medical centers during 2019
Tebipenem HBR
Epidemiology of complicated urinary tract infections (cUTIs) presenting in emergency departments across the United States (US)
Tebipenem HBR
Clinical characteristics and demographics of patients with complicated urinary tract infections (cUTI) and antibiotic resistance or treatment failure: a retrospective database analysis
Tebipenem HBR
Eligibility and outcomes of conversion to oral (PO) therapy in patients hospitalized with Enterobacteriaceae (ENT) urinary tract infection (UTI) in the United States (US): a multicenter analysis
Tebipenem HBR
Hospital admission patterns in adult patients with complicated urinary tract infections: identification of potentially avoidable hospital admissions across US hospitals
SPR206
Brown P, Abdulle O, Boakes S, et al. Influence of Lipophilicity on the Antibacterial Activity of Polymyxin Derivatives and on Their Ability to Act as Potentiators of Rifampicin. ACS Infect Dis. 2021 Apr 9;7(4):894-905.
SPR720
Pennings LJ, Ruth MM, Wertheim HFL, van Ingen J. The Benzimidazole SPR719 Shows Promising Concentration-Dependent Activity and Synergy against Nontuberculous Mycobacteria. Antimicrob Agents Chemother. 2021 Mar 18;65(4):e02469-20.
Tebipenem HBR
Clayton NP, Jain A, Halasohoris SA, et al. In vitro and in vivo characterization of tebipenem (TBP), an orally active carbapenem, against biothreat pathogens. Antimicrob Agents Chemother. 2021 Feb 16:AAC.02385-20.
Tebipenem HBR
Zilberberg MD, Nathanson BH, Sulham K, Shorr AF. Multiple antimicrobial resistance and outcomes among hospitalized patients with complicated urinary tract infections in the US, 2013-2018: a retrospective cohort study. BMC Infect Dis. 2021 Feb 8;21(1):159.
Tebipenem HBR
Critchley IA, Cotroneo N, Pucci MJ, Jain A, Mendes RE. Resistance among urinary tract pathogens collected in Europe during 2018. J Glob Antimicrob Resist. 2020 Dec;23:439-444.
Tebipenem HBR
Clinical characteristics and demographics of patients with complicated urinary tract infections (cUTI) and antibiotic resistance or treatment failure: a retrospective database analysis
SPR720
Evaluating the activity of SPR719 a novel aminobenzimidazole against nontuberculous Mycobacteria
Tebipenem HBR
Characterization of tebipenem pivoxil hydrobromide pharmacokinetics-pharmacodynamics in a neutropenic murine acute pyelonephritis model
SPR720
Phase 1 first-in-human single-and multiple-ascending dose trial demonstrates pharmacokinetics and tolerability of SPR720, an oral DNA GyrB inhibitor for Mycobacterial infections
SPR720
Pharmacokinetics/pharmacodynamics of the novel gyrase inhibitor SPR719/SPR720 and clinical dose selection to treat pulmonary Mycobacterium avium complex disease
SPR720
SPR720, a novel aminobenzimidazole gyrase inhibitor, demonstrates potent efficacy against Mycobacterium avium ATCC 700898 in a chronic C3HeBFeJ mouse infection model
SPR206
Activity of SPR206, a polymyxin derivative, compared to colistin alone and in combination against multidrug-resistant Pseudomonas aeruginosa strains
Tebipenem HBR
Hospital admission patterns in adult patients with complicated urinary tract infections: identification of potentially avoidable hospital admissions across US hospitals
Tebipenem HBR
Eligibility and outcomes of conversion to oral (PO) therapy in patients hospitalized with Enterobacteriaceae (ENT) urinary tract infection (UTI) in the United States (US): a multicenter analysis
Tebipenem HBR
Pre and post hospitalization resource utilization and costs associated with urinary tract infection (UTI) in both commercial and Medicare populations
Tebipenem HBR
Tebipenem: An oral carbapenem with activity against multi-drug resistant urinary tract infection isolates of Escherichia coli collected from US medical centers during 2019
Tebipenem HBR
Health resource utilization in patients with complicated urinary tract infections (cUTI) and antibiotic resistance or treatment failure: a retrospective database analysis
Tebipenem HBR
Epidemiology of complicated urinary tract infections (cUTIs) presenting in emergency departments across the United States (US)
Tebipenem HBR
Oral tebipenem pivoxil hydrobromide is non-inferior to IV ertapenem in complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) – Results from the pivotal ADAPT-PO study.
Tebipenem HBR
Hospital costs and reimbursement in patients with resistant Enterobacteriaceae (ENT) urinary tract infection (UTI) in the United States (US): a multicenter analysis
Tebipenem HBR
Zilberberg MD, Nathanson BH, Sulham K, Shorr AF. Antimicrobial Susceptibility and Cross-Resistance Patterns among Common Complicated Urinary Tract Infections in U.S. Hospitals, 2013 to 2018. Antimicrob Agents Chemother. 2020 Jul 22;64(8):e00346-20.
Tebipenem HBR
Cotroneo N, Rubio A, Critchley IA, et al. In vitro and in vivo characterization of tebipenem, an oral carbapenem. Antimicrob Agents Chemother. 2020 Jul 22;64(8):e02240-19.
SPR720
Stokes SS, Vemula R, Pucci MJ. Advancement of GyrB Inhibitors for Treatment of Infections Caused by Mycobacterium tuberculosis and Non-tuberculous Mycobacteria. ACS Infect Dis. 2020 Jun 12;6(6):1323-1331.
SPR206
Brown P, Abbott E, Abdulle O, et al. Design of Next Generation Polymyxins with Lower Toxicity: The Discovery of SPR206. ACS Infect Dis. 2019 Oct 11;5(10):1645-1656.
Tebipenem HBR
Characterization of tebipenem pharmacokinetics-pharmacodynamics for efficacy against Enterobacteriaceae in a one-compartment in vitro infection model
Unable to find what you were looking for?
Download a complete bibliography from each of our ongoing investigational programs below.
